Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis.

ESC Heart Fail · 2022 · PMC9065811 · PMID 35384369

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

The 180 day survival outcomes showed a trend towards better results with milrinone, compared with dobutamine, but they also did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.